Non-absorbable antibiotics in the treatment of diverticular disease of the colon.
Diverticular disease of the colon is a common health problem in western societies. Most patients with colonic diverticula are asymptomatic; it has been estimated that only 20% of individuals harboring diverticula will develop symptoms and signs of illness and a minority will develop major complications. Medical treatment of diverticular disease is aimed to the relief of symptoms and to prevent inflammatory complications. High fiber diets and antispasmodics are widely used in the treatment of uncomplicated diverticular disease although their real efficacy has not been fully elucidated. Antibiotics are used to treat major inflammatory complications of diverticular disease but apparently there is no rationale for their use in uncomplicated disease where an inflammatory component is, by definition, excluded. However two recent papers suggest a possible role of rifaximin, a broad-spectrum poorly absorbable antibiotic, in the management of mild acute diverticulitis and in obtaining symptomatic relief in patients with uncomplicated disease. Prospective studies with an adequate sample size per group of treatment are needed to assess the efficacy of cyclic long term administration of poorly absorbable antibiotics in preventing major complications of diverticular disease.
Papi
C
C
Servizio Gastroenterologia, Ospedale S. Filippo Neri, Roma, Italy.
Camarri
E
E
D001424:Bacterial Infections / Q000188:drug therapy*; D004043:Dietary Fiber / Q000008:administration & dosage; D004239:Diverticulitis, Colonic / Q000188:drug therapy* / Q000382:microbiology; D004241:Diverticulum, Colon / Q000382:microbiology / Q000628:therapy; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology; D008351:Mannans / Q000627:therapeutic use; D012294:Rifamycins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000078262:Rifaximin
D004043:Dietary Fiber; D008351:Mannans; D012294:Rifamycins; C022901:(1-6)-alpha-glucomannan; D000078262:Rifaximin